Potential bias and mitigations when using stable isotope labeled parent drug as internal standard for LC-MS/MS quantitation of metabolites

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 31, 2010, Pages 3267-3276

  Jian, Wenying ^a   Edom, Richard W ^a   Xu, Yaodong ^a   Gallagher, Joseph ^a   Weng, Naidong ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Ion suppression; LC MS MS; Metabolite; Quantitation; Safety assessment; Stable isotope labeled internal standard

Indexed keywords

ION SUPPRESSION; LC-MS/MS; QUANTITATION; SAFETY ASSESSMENTS; STABLE ISOTOPE LABELED INTERNAL STANDARDS;

ATMOSPHERIC IONIZATION; ATMOSPHERIC PRESSURE; BIOMOLECULES; CHEMICAL COMPOUNDS; IONIZATION; IONS; ISOTOPES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PARTICLE DETECTORS; RISK PERCEPTION; SAFETY ENGINEERING; STANDARDS;

METABOLITES;

4 HYDROXYPROPRANOLOL; ISOTOPE; PROPRANOLOL;

ARTICLE; ATMOSPHERIC PRESSURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SAFETY; DRUG STRUCTURE; HUMAN; INTERNAL BIAS; LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; STANDARD; TANDEM MASS SPECTROMETRY;

ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CLINICAL TRIALS AS TOPIC; HUMANS; ISOTOPE LABELING; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; PROPRANOLOL; RATS; REFERENCE STANDARDS; REGRESSION ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 78449291591     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.10.008     Document Type: Article

References (24)

1. Baillie T.A., Cayen M.N., Fouda H., Gerson R.J., Green J.D., Grossman S.J., Klunk L.J., LeBlanc B., Perkins D.G., Shipley L.A. Toxicol. Appl. Pharmacol. 2002, 182:188.
2. Evans D.C., Watt A.P., Nicoll-Griffith D.A., Baillie T.A. Chem. Res. Toxicol. 2004, 17:3.
3. Liebler D.C., Guengerich F.P. Nat. Rev. Drug Discov. 2005, 4:410.
4. Leclercq L., Cuyckens F., Mannens G.S., de Vries R., Timmerman P., Evans D.C. Chem. Res. Toxicol. 2009, 22:280.
5. FDA, Guidance for Industry: Safety Testing of Drug Metabolites (2008).
6. ICH, CPMP/ICH/286/95 ICH Topic M3 (R2) Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals
7. Faed E.M. Drug Metab. Rev. 1984, 15:1213.
8. Jian W., Edom R.W., Xu Y., Weng N. J. Sep. Sci. 2010, 33:681.
9. FDA, Guidance for Industry: Bioanalytical Validation (2001).
10. Tong X.S., Wang J., Zeng S., Pivnichny J.V., Griffin P.R., Shen X., Donnelly M., Cakerich K., Nunes C., Fenyk-Melody J. Anal. Chem. 2002, 74:6305.
11. Liang H.R., Foltz R.L., Meng M., Bennett P. Rapid Commun. Mass Spectrom. 2003, 17:2815.
12. Sojo L.E., Lum G., Chee P. Analyst 2003, 128:51.
13. Remane D., Wissenbach D.K., Meyer M.R., Maurer H.H. Rapid Commun. Mass Spectrom. 2010, 24:859.
14. Cech N.B., Enke C.G. Anal. Chem. 2001, 73:4632.
15. Enke C.G. Anal. Chem. 1997, 69:4885.
16. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Anal. Chem. 1998, 70:882.
17. Schuhmacher J., Zimmer D., Tesche F., Pickard V. Rapid Commun. Mass Spectrom. 2003, 17:1950.
18. Jemal M., Xia Y.Q. Rapid Commun. Mass Spectrom. 1999, 13:97.
19. Jemal M., Ouyang Z., Xia Y.Q. Biomed. Chromatogr. 2009, 24:2.
20. Ramanathan R., Su A.D., Alvarez N., Blumenkrantz N., Chowdhury S.K., Alton K., Patrick J. Anal. Chem. 2000, 72:1352.
21. Little J.L., Wempe M.F., Buchanan C.M. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006, 833:219.
22. Shou W.Z., Naidong W. Rapid Commun. Mass Spectrom. 2003, 17:589.
23. Jemal M., Ouyang Z., Xia Y.Q. Biomed. Chromatogr. 2010, 24:2.
24. Xu X., Mei H., Wang S., Zhou Q., Wang G., Broske L., Pena A., Korfmacher W.A. Rapid Commun. Mass Spectrom. 2005, 19:2643.